Close

Stifel Starts Rocket Pharmaceuticals (RCKT) at Buy

March 1, 2021 4:06 PM EST Send to a Friend
Stifel analyst Dae Gon Ha initiates coverage on Rocket Pharmaceuticals (NASDAQ: RCKT) with a Buy rating and a price target ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login